4
Changes in Ownership
Spyre Therapeutics, Inc. Filed Acc 0001209191-22-036085
Chief Commercial Officer bought 28,200 shares at $0.71 ($20,022)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hanley Jr. Michael Conick Chief Commercial Officer | 2022-06-08 | Purchase | +28,200 | $0.71 | $20,022 | 36,200 | D: show line 1 in the form |
| Open-market purchases · 28,200 sh · avg $0.71 · $20,022 | |||||||
Loading xslF345X03/doc4.xml…